Compagnie Lombard Odier SCmA’s Avadel Pharmaceuticals AVDL Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,000	Closed	-$65.6K	–	445
2024 Q3	$65.6K	Sell	5,000 -2,500	-33%	-$38.1K	﹤0.01%	322
2024 Q2	$105K	Sell	7,500 -4,500	-38%	-$73.3K	﹤0.01%	281
2024 Q1	$203K	Hold	12,000	–	–	﹤0.01%	255
2023 Q4	$169K	Hold	12,000	–	–	﹤0.01%	303
2023 Q3	$124K	Hold	12,000	–	–	﹤0.01%	332
2023 Q2	$198K	Hold	12,000	–	–	0.01%	266
2023 Q1	$110K	Sell	12,000 -40,000	-77%	-$329K	﹤0.01%	365
2022 Q4	$372K	Buy	52,000 +33,000	+174%	+$231K	0.01%	222
2022 Q3	$95K	Hold	19,000	–	–	﹤0.01%	392
2022 Q2	$47K	Hold	19,000	–	–	﹤0.01%	441
2022 Q1	$130K	Buy	19,000 +13,000	+217%	+$89.4K	﹤0.01%	352
2021 Q4	$48K	Hold	6,000	–	–	﹤0.01%	511
2021 Q3	$59K	Hold	6,000	–	–	﹤0.01%	488
2021 Q2	$40K	Hold	6,000	–	–	﹤0.01%	509
2021 Q1	$54K	Hold	6,000	–	–	﹤0.01%	498
2020 Q4	$40K	Hold	6,000	–	–	﹤0.01%	462
2020 Q3	$30K	Hold	6,000	–	–	﹤0.01%	431
2020 Q2	$48K	Sell	6,000 -13,000	-68%	-$115K	﹤0.01%	377
2020 Q1	$151K	Hold	19,000	–	–	0.01%	262
2019 Q4	$143K	Hold	19,000	–	–	0.01%	279
2019 Q3	$79K	Hold	19,000	–	–	﹤0.01%	327
2019 Q2	$55K	Hold	19,000	–	–	﹤0.01%	355
2019 Q1	$28K	Hold	19,000	–	–	﹤0.01%	445
2018 Q4	$49K	Hold	19,000	–	–	﹤0.01%	391
2018 Q3	$83K	Hold	19,000	–	–	﹤0.01%	374
2018 Q2	$117K	Hold	19,000	–	–	﹤0.01%	339
2018 Q1	$139K	Sell	19,000 -19,000	-50%	-$167K	0.01%	344
2017 Q4	$312K	Buy	38,000 +19,000	+100%	+$178K	0.01%	345
2017 Q3	$199K	Buy	+19,000	New	+$181K	0.01%	368
2017 Q1	–	Sell	-3,000	Closed	-$31K	–	726
2016 Q4	$31K	Hold	3,000	–	–	﹤0.01%	663
2016 Q3	$37K	Hold	3,000	–	–	﹤0.01%	721
2016 Q2	$32K	Hold	3,000	–	–	﹤0.01%	725
2016 Q1	$33K	Hold	3,000	–	–	﹤0.01%	767
2015 Q4	$37K	Hold	3,000	–	–	﹤0.01%	731
2015 Q3	$49K	Hold	3,000	–	–	﹤0.01%	608
2015 Q2	$64K	Hold	3,000	–	–	﹤0.01%	615
2015 Q1	$54K	Buy	+3,000	New	+$47K	﹤0.01%	774

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Compagnie Lombard Odier SCmA's AVDL Position: Q4 2024 in Review

Compagnie Lombard Odier SCmA sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 5,000 shares — an estimated $65.6K sold.

Compagnie Lombard Odier SCmA first reported a position in AVDL in Q1 2015 and held it in 37 quarters. The position peaked at $372K in Q4 2022. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

Compagnie Lombard Odier SCmA reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 5,000 Avadel Pharmaceuticals shares in Q4 2024, an estimated $65.6K.
Compagnie Lombard Odier SCmA first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 37 quarters.
Compagnie Lombard Odier SCmA's Avadel Pharmaceuticals position peaked at $372K in Q4 2022.
159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2024, filed 30 Jan 2025.